Analysed ONCOLYTICS BIOTECH INC (ONCY:NASDAQ) News Sources
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
22-05-2026
yahoo.com
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
26-05-2026
yahoo.com
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
01-06-2026
yahoo.com
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study
01-06-2026
stocktwits.com
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
02-06-2026
yahoo.com
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention
04-06-2026
yahoo.com
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
16-06-2026
yahoo.com
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics
16-06-2026
stocktwits.com
What is the current price of ONCOLYTICS BIOTECH INC (ONCY:NASDAQ)?
The current price of ONCOLYTICS BIOTECH INC (ONCY:NASDAQ) is $0.9495.
ONCOLYTICS BIOTECH INC (ONCY:NASDAQ) absolute price change since previous trading day?
The absolute price change of ONCOLYTICS BIOTECH INC (ONCY:NASDAQ) since the previous trading day is $0.0993.
ONCOLYTICS BIOTECH INC (ONCY:NASDAQ) percentage price change since previous trading day?
The percentage price change of ONCOLYTICS BIOTECH INC (ONCY:NASDAQ) since the previous trading day is 11.6796%.
What is the most recent average sentiment score for ONCOLYTICS BIOTECH INC (ONCY:NASDAQ)?
The most recent average sentiment score for ONCOLYTICS BIOTECH INC (ONCY:NASDAQ) is 65 out of 100.
What is the most recent average sentiment for ONCOLYTICS BIOTECH INC (ONCY:NASDAQ)?
The most recent sentiment for ONCOLYTICS BIOTECH INC (ONCY:NASDAQ) is .
SEC-8K** Filing Available For ONCOLYTICS BIOTECH INC (ONCY:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.